STOCK TITAN

[Form 4] The Cigna Group Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

David J. Brailer, EVP & Chief Health Officer of The Cigna Group (CI), reported a transaction on 08/29/2025 showing 290 shares of Cigna common stock were disposed of at a price of $300.66 per share. The filing states these shares were withheld to satisfy tax obligations upon the vesting of restricted shares, not a market sale.

After the withholding, Mr. Brailer beneficially owns 17,525 shares of Cigna common stock. The Form 4 was executed by an attorney-in-fact and filed on 09/02/2025.

David J. Brailer, EVP e Chief Health Officer di The Cigna Group (CI), ha segnalato una transazione il 08/29/2025 che indica che 290 azioni ordinarie di Cigna sono state trattenute a un prezzo di $300.66 per azione. Il documento specifica che queste azioni sono state trattenute per adempiere a obblighi fiscali alla maturazione di azioni vincolate, e non si tratta di una vendita sul mercato.

Dopo la ritenuta, il Sig. Brailer detiene effettivamente 17.525 azioni ordinarie di Cigna. Il Modulo 4 è stato eseguito da un procuratore ed è stato depositato il 09/02/2025.

David J. Brailer, EVP y Chief Health Officer de The Cigna Group (CI), informó una transacción el 08/29/2025 en la que se indica que se retuvieron 290 acciones ordinarias de Cigna a un precio de $300.66 por acción. El informe señala que estas acciones fueron retenidas para satisfacer obligaciones fiscales al consolidarse acciones restringidas, y no constituyen una venta en el mercado.

Tras la retención, el Sr. Brailer posee de forma beneficiaria 17.525 acciones ordinarias de Cigna. El Formulario 4 fue firmado por un apoderado y presentado el 09/02/2025.

David J. Brailer, The Cigna Group(CI)의 EVP 겸 Chief Health Officer는 2025년 08월 29일자로 Cigna 보통주 290주가 처분(실제 시장매도는 아님)된 내역을 보고했습니다. 주당 가격은 $300.66이었습니다. 신고서에는 이 주식들이 제한 주식의 권리 확정(vesting) 시점에 세금 의무를 충족하기 위해 원천징수된 것이며 시장 매도는 아니라고 명시되어 있습니다.

원천징수 후 Brailer 씨는 17,525주의 Cigna 보통주를 실질적으로 보유하고 있습니다. Form 4는 대리인에 의해 서명되어 2025년 09월 02일 제출되었습니다.

David J. Brailer, EVP et Chief Health Officer de The Cigna Group (CI), a déclaré une transaction le 08/29/2025 indiquant que 290 actions ordinaires Cigna ont été retenues à un prix de $300.66 par action. Le dépôt précise que ces actions ont été retenues pour satisfaire des obligations fiscales lors de la levée des restrictions des actions (vesting), et non qu'il s'agit d'une vente sur le marché.

Après cette retenue, M. Brailer détient à titre bénéficiaire 17 525 actions ordinaires Cigna. Le Formulaire 4 a été signé par un mandataire et déposé le 09/02/2025.

David J. Brailer, EVP & Chief Health Officer der The Cigna Group (CI), meldete am 08/29/2025 eine Transaktion, bei der 290 Stück Cigna-Stammaktien einbehalten wurden zu einem Preis von $300.66 pro Aktie. Die Einreichung gibt an, dass diese Aktien zur Erfüllung steuerlicher Verpflichtungen bei der Vesting von eingeschränkten Aktien einbehalten wurden und nicht durch einen Marktverkauf veräußert wurden.

Nach dem Einbehalt besitzt Herr Brailer wirtschaftlich 17.525 Aktien der Cigna-Stammaktien. Das Formular 4 wurde von einem Bevollmächtigten ausgeführt und am 09/02/2025 eingereicht.

Positive
  • Clear disclosure that the 290-share disposition was for tax withholding on vested restricted stock
  • Compliance with Section 16 reporting, including execution by attorney-in-fact and timely filing
Negative
  • None.

Insights

TL;DR Routine tax-withholding of vested restricted shares; immaterial to Cigna’s capital structure.

The reported 290-share disposition at $300.66 per share reflects tax withholding on vested restricted stock rather than an active open-market sale, which typically has minimal signaling value to investors. The remaining beneficial ownership of 17,525 shares provides context on the insider's stake size. No new derivative positions or additional dispositions are reported, and the transaction appears consistent with standard executive compensation mechanics.

TL;DR Disclosure follows Section 16 requirements and clarifies the nature of the share transfer.

The Form 4 documents proper disclosure for an insider compensation-related withholding event. Filing by an attorney-in-fact is noted and acceptable when executed under power of attorney. The transaction description explicitly states tax-withholding as the reason, which helps distinguish it from trading for liquidity or other motives that might raise governance concerns.

David J. Brailer, EVP e Chief Health Officer di The Cigna Group (CI), ha segnalato una transazione il 08/29/2025 che indica che 290 azioni ordinarie di Cigna sono state trattenute a un prezzo di $300.66 per azione. Il documento specifica che queste azioni sono state trattenute per adempiere a obblighi fiscali alla maturazione di azioni vincolate, e non si tratta di una vendita sul mercato.

Dopo la ritenuta, il Sig. Brailer detiene effettivamente 17.525 azioni ordinarie di Cigna. Il Modulo 4 è stato eseguito da un procuratore ed è stato depositato il 09/02/2025.

David J. Brailer, EVP y Chief Health Officer de The Cigna Group (CI), informó una transacción el 08/29/2025 en la que se indica que se retuvieron 290 acciones ordinarias de Cigna a un precio de $300.66 por acción. El informe señala que estas acciones fueron retenidas para satisfacer obligaciones fiscales al consolidarse acciones restringidas, y no constituyen una venta en el mercado.

Tras la retención, el Sr. Brailer posee de forma beneficiaria 17.525 acciones ordinarias de Cigna. El Formulario 4 fue firmado por un apoderado y presentado el 09/02/2025.

David J. Brailer, The Cigna Group(CI)의 EVP 겸 Chief Health Officer는 2025년 08월 29일자로 Cigna 보통주 290주가 처분(실제 시장매도는 아님)된 내역을 보고했습니다. 주당 가격은 $300.66이었습니다. 신고서에는 이 주식들이 제한 주식의 권리 확정(vesting) 시점에 세금 의무를 충족하기 위해 원천징수된 것이며 시장 매도는 아니라고 명시되어 있습니다.

원천징수 후 Brailer 씨는 17,525주의 Cigna 보통주를 실질적으로 보유하고 있습니다. Form 4는 대리인에 의해 서명되어 2025년 09월 02일 제출되었습니다.

David J. Brailer, EVP et Chief Health Officer de The Cigna Group (CI), a déclaré une transaction le 08/29/2025 indiquant que 290 actions ordinaires Cigna ont été retenues à un prix de $300.66 par action. Le dépôt précise que ces actions ont été retenues pour satisfaire des obligations fiscales lors de la levée des restrictions des actions (vesting), et non qu'il s'agit d'une vente sur le marché.

Après cette retenue, M. Brailer détient à titre bénéficiaire 17 525 actions ordinaires Cigna. Le Formulaire 4 a été signé par un mandataire et déposé le 09/02/2025.

David J. Brailer, EVP & Chief Health Officer der The Cigna Group (CI), meldete am 08/29/2025 eine Transaktion, bei der 290 Stück Cigna-Stammaktien einbehalten wurden zu einem Preis von $300.66 pro Aktie. Die Einreichung gibt an, dass diese Aktien zur Erfüllung steuerlicher Verpflichtungen bei der Vesting von eingeschränkten Aktien einbehalten wurden und nicht durch einen Marktverkauf veräußert wurden.

Nach dem Einbehalt besitzt Herr Brailer wirtschaftlich 17.525 Aktien der Cigna-Stammaktien. Das Formular 4 wurde von einem Bevollmächtigten ausgeführt und am 09/02/2025 eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BRAILER DAVID J

(Last) (First) (Middle)
900 COTTAGE GROVE ROAD

(Street)
BLOOMFIELD CT 06002

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & Chief Health Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.01 Par Value 08/29/2025 F 290(1) D $300.66 17,525 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.
Tyler Gratton, attorney-in-fact 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did David J. Brailer report on Form 4 for CI?

He reported a disposition of 290 shares on 08/29/2025 at $300.66 per share, withheld to satisfy tax obligations on vested restricted shares.

How many Cigna (CI) shares does the reporting person own after the transaction?

The filing shows beneficial ownership of 17,525 shares following the reported transaction.

Was the 290-share transaction an open-market sale?

No. The Form 4 states the shares were withheld to satisfy tax obligations upon vesting of restricted shares.

Who signed and filed the Form 4 for David J. Brailer?

The form was executed by an attorney-in-fact, Tyler Gratton, and filed on 09/02/2025.

What is the price per share reported on the transaction?

The transaction price reported is $300.66 per share.
Cigna Group

NYSE:CI

CI Rankings

CI Latest News

CI Latest SEC Filings

CI Stock Data

81.15B
262.66M
1.59%
90.16%
0.92%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
BLOOMFIELD